ZANTE GREG (Chief Financial Officer) sold 9.1% of their position (21.22K shares) of VIKING THERAPEUTICS, INC. on the open market
Open‑market sale worth $710.1K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 7/30/2026ACC: 0001193125-26-324447
Officer· Chief Financial Officer
Since Jan 2021
+10.45K
Net shares
Net buyer
$710.1K
Total sold
1
Open market trades
0B · 1S
2
Total transactions
31.67K acquired · 21.22K disposed
Non-Derivative Transactions2
Common Stock, par value $0.00001 per share
Direct
Shares
+31.67K
Price / share
—
Trade value
—
% of position
15.7%
7/28/2026
201.75K→233.42K
Common Stock, par value $0.00001 per share
Direct
Shares
−21.22K
Price / share
$33.47
Trade value
$710.14K
% of position
9.1%
7/29/2026
233.42K→212.20K
Total
Net shares
+10.45K
Net value
-$710.14K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.00001 per share Direct | 7/28/2026 | A · Award | +31.67K | — | — | 15.7% | 201.75K | 233.42K |
| Common Stock, par value $0.00001 per share Direct | 7/29/2026 | S · Sale | −21.22K | $33.47 | $710.14K | 9.1% | 233.42K | 212.20K |
| Total | +10.45K | -$710.14K | ||||||
Derivative Transactions0
No derivative transactions reported